| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
General Counsel &Corp Sec | General Counsel &Corp Sec
1 company
Allan Jonathan is a General Counsel &Corp Sec at STOK. Recent filings cover 0 purchases and 27 sales. Those positions are worth an estimated $475K at current prices.
Our model assigns Allan Jonathan a below-average insider score of 46/100, based on 19 past trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -45.9%.
Allan Jonathan's largest disclosed position is in STOK as General Counsel &Corp Sec, worth about $475K. The recent filings there lean toward selling, a net 111,464 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 20, 2024 | STOK Stoke Therapeutics, Inc. | General Counsel &Corp Sec | Sale+OE | 8,599 | $15.04 | $129,327.24 | -76.8% | -7.8% | -37.6% | |
| Mar 28, 2024 | STOK Stoke Therapeutics, Inc. | General Counsel &Corp Sec | Sell | 5,126 | $13.20 | $67,667.91 | -49.2% | -4.3% | -46.6% | |
| Mar 19, 2024 | STOK Stoke Therapeutics, Inc. | General Counsel &Corp Sec | Sale+OE | 2,349 | $6.10 | $14,325.61 | -23.3% | +169.0% | +42.4% | |
| Jun 21, 2023 | STOK Stoke Therapeutics, Inc. | General Counsel &Corp Sec | Sell | 1,948 | $13.48 | $26,252.22 | -100% | -64.7% | +9.3% |